DGAP-News

Neovacs Installs a New International Scientific Committee in New York

DGAP-News: Neovacs S.A. / Key word(s): Strategic Company Decision
Neovacs Installs a New International Scientific Committee in New York

10.10.2014 / 08:00

---------------------------------------------------------------------

Neovacs Installs a New International Scientific Committee in New York


Paris, 10 October 2014 - NEOVACS (Alternext Paris : ALNEV), a leader in
active immunotherapies for the treatment of autoimmune diseases, announced
the installation today of its new international scientific committee in New
York.

In order to strengthen its scientific base and increase the visibility in
the scientific community of its innovative technology in the treatment of
autoimmune diseases, Neovacs has decided to be supported in its development
by an international Scientific Committee which will meet in New York on a
regular basis. This committee is composed of leading world experts in the
activity fields of Neovacs, immune therapy, chronical inflammatory and
autoimmune diseases.

This Committee will be chaired by Professor Jacques Banchereau, Jackson
Laboratory for Genomic Medicine, Farmington, CT, USA and be composed of:

Prof. David G.Brooks, Phd
UCLA, Los Angeles, CA

Prof. Jean-Frédéric Colombel, MD
Helmsley Inflammatory Bowel Disease center
Icahn School of Medicine at Mount Sinai
The Mount Sinai Hospital, New York, NY

Prof. Michael Ehrenstein, MB BS, PhD, FRCP
University College London, London, UK

Prof. Paul Emery, MA MD FRCP
University of Leeds, Leeds, UK

Prof. Bernard Lauwerys, MD, PhD
Cliniques Universitaire St Luc & Université Catholique de Louvain,
Brussels, Belgium

Prof. Miriam Merad, MD, PhD
Icahn School of Medicine at Mount Sinai
The Mount Sinai Hospital, New York, NY

Prof. Virginia Pascual, MD
Baylor Institute for Immunology Research, Dallas, TX

Their mission will consist of advising the company in its therapeutic
targets on the base of their scientific and clinical experience in
immunotherapy and in the choices to be taken within the preclinical and
clinical developments of its products.

Miguel Sieler, CEO of Neovacs declared: "We are very happy and very proud
to be able to count in the future on the advice of this new International
Scientific Committee. Its location in New York is an important step in our
strategy to develop our activity in the USA".


About Neovacs

Neovacs is a biotechnology company focused on an active immunotherapy
technology platform (Kinoids) with applications in autoimmune and/or
inflammatory diseases. On the basis of the company's proprietary technology
for inducing a polyclonal immune response (covered by six patent families
that run until at least 2023) Neovacs is focusing its development efforts